President - John Kane, MD
John Kane received his BA from Cornell University and his MD from the New York University School of Medicine. He trained in psychiatry at The Zucker Hillside Hospital in New York, where he subsequently served as Director of Research and then Chairman of Psychiatry. He is currently Vice President for Behavioral Health Services at the North Shore Long Island Jewish Health System and Professor and Chairman of Psychiatry at the Hofstra-North Shore LIJ School of Medicine. For most of his career he has focused on research in psychopharmacology and psychobiology in schizophrenia. He currently directs the NIMH Advanced Center for Services and Interventions Research in Early Phase Psychosis at The Zucker Hillside Hospital and The Feinstein Institute for Medical Research. Dr. Kane has served as Chairman of the Psychopharmacologic Drugs Advisory Committee of the Food and Drug Administration and chaired the Research Review Committee, National Institute of Mental Health Psychobiology and Psychopathology Review Committee for the NIMH where he has also been a member of the Board of Scientific Advisors. He is currently also serving as President of the American Society of Clinical Psychopharmacology. Dr Kane has received a number of awards for his research including the Arthur P. Noyes Award in Schizophrenia, the NAPPH Presidential Award in the Field of Research, the American Psychiatric Association Foundations' Fund Prize for Research in Psychiatry, the Kempf Fund Award for Research Development in Psychobiological Psychiatry, the Lieber Prize for Outstanding Research in Schizophrenia, the Heinz Lehmann Research Award and the Dean Award for Schizophrenia Research from the American College of Psychiatrists. He has authored over 300 publications and serves on the editorial boards of numerous journals. Dr. Kane’s research has benefited enormously from the collaboration of numerous colleagues, patients and families, for which he is very grateful.
President Elect - René Kahn, M.D., Ph.D.
Dr. René Kahn is Professor and Chair of the Department of Psychiatry and Head of the Division of Neuroscience at the University medical Center, Utrecht, the Netherlands. In 1995 he received a Fulbright Scholarship for study at Yale and subsequently did a Fellowship in Biological Psychiatry at the Montefiore Hospital and Albert Einstein College of Medicine in New York. He then moved to the Mount Sinai School of Medicine where he conducted schizophrenia research and became Unit Chief of one of the research units. Dr. Kahn has received many grants for his research into the origins and treatments of schizophrenia. He is currently leading a large European consortium to improve treatment of first-episode schizophrenia patients. His current research interests include neuroimaging in schizophrenia and the genetic dissection of completx traits in specific psychiatric disorders. He has published over 450 research papers and book chapters. He is/was on the editorial boards of Schizophrenia Research, Schizophrenia Bulletin, Early Interventions in Psychiatry and European Neuropsychopharmacology. He is Treasurer of the Schizophrenia International Research Society. He is a member of the Neuroscience and Mental Health Board of the Medical Research Council of the UK and of the scientific advisory group for CNS of the European Medicines Agency. In 2009 he was elected as a member of the Royal Netherlands Academy of Arts and Sciences.
Past President - Professor Sir Robin Murray, MD
Robin Murray graduated from the University of Glasgow, Scotland and subsequently trained in internal medicine there. He then went to study Psychiatry at the Maudsley Hospital in London and indeed has spent most of his working life there apart from one year at NIMH in the USA. He has been Dean and Professor of Psychiatry at the associated Institute of Psychiatry (Kings College, London) and is now Professor of Psychiatric Research there. He has written numerous papers, not all of them boring. His particular interest is in understanding the causes of psychosis, and he and his colleagues contributed to the establishment of neurodevelopmental model of schizophrenia. Robin Murray's group furthered our understanding that environmental factors such as obstetric events, heavy cannabis use and migration increase the risk of developing schizophrenia. Robin Murray is also involved in developing and implementing new treatments for psychotic illnesses, and cares for people with psychosis at the South London and Maudsley NHS Trust. He is the fourth British psychiatrist to become a Fellow of the Royal Society, London and according to the Web of Science, he is the second most frequently cited psychiatric researcher outside the USA. He has been blessed with wonderful colleagues and students, has supervised 42 PhDs, and 35 of his students have become professors
Secretary - Lynn E. DeLisi, M.D.
Lynn E. DeLisi, MD is currently Attending Psychiatrist in the VA Boston Healthcare System situated in Brockton, Massachusetts and Professor of Psychiatry at Harvard Medical School. In addition, she is the co-editor-in-chief and co-founder of the Elsevier journal, Schizophrenia Research and secretary, as well as co-founder, of two professional organizations: The Schizophrenia International Research Society (SIRS) and The International Society of Psychiatric Genetics (ISPG).Her undergraduate degree is in zoology from The University of Wisconsin, Madison, Wisconsin. She obtained her M.D. degree from the Medical College of Pennsylvania in 1972 and went on from there to do 3 years of general practice work with the migrant chile farmers of Northern New Mexico. From 1975-1978 she completed a residency in psychiatry at Saint Elizabeth's Hospital, Washington, DC. From 1978-1987 she was a post-doctoral fellow and then a full-time staff research psychiatrist in the NIMH intramural research program, St. Elizabeth's Hospital and Bethesda, Maryland. In 1987, she moved to The State University of New York at Stony Brook where she set up several research programs on the longitudinal biological outcome of schizophrenia emphasizing both brain imaging and genetic studies. From 2001 through 2008 she was professor at New York University School of Medicine and Associate Director of the brain imaging division at The Nathan Kline Institute for Psychiatric Research. She moved to her current position in the Boston area in January 2009. She is a fellow of the American College of Neuropsychopharmacology, and on the Board of several other organizations and journal editorial boards. She has edited and authored over 300 books and manuscripts and serves on the editorial board of several other journals. Her book, 100 Questions and Answers about Schizophrenia: Painful Minds has been circulated widely among families of people with schizophrenia and medical students internationally and has been translated into Japanese and Spanish, as well other languages besides English.
Treasurer - Tony A. Grace, Ph.D.
Dr. Anthony A. Grace is a Distinguished Professor of Neuroscience and a Professor of Psychiatry and Psychology at the University of Pittsburgh in Pittsburgh, PA. He received his Ph.D. from Yale University School of Medicine with Dr. Benjamin S. Bunney and had postdoctoral training with Dr. Rodolfo Llinas in the Department of Physiology and Biophysics at New York University School of Medicine. Dr. Grace has been involved in translational research related to the dopamine system for over 30 years. His early work pioneered the identification and characterization of dopamine-containing neurons, and was the first to provide a means to quantify their activity state and pattern in a way that is the standard in the literature, all while working as a graduate student. His current work involves looking at the interactions of several brain regions with known involvement in schizophrenia and drug abuse, including the hippocampus, prefrontal cortex, and amygdala, and how these interactions are disrupted by stress. His most recent work has used the MAM developmental model of schizophrenia, which was developed in his lab. Using this model, he found that the hyperdopaminergic state believed to be present in schizophrenia appears to be a direct result of overdrive of the dopamine system by the hippocampus. Moreover, this is driven by a loss of function in parvalbumin interneurons, which also is responsible for disruption of gamma rhythmicity. Using this model, his lab has now advanced novel GABAergic drugs that may be effective in the treatment of schizophrenia. Dr. Grace has received several awards for his research, including the Paul Janssen Schizophrenia Research Award and the Lilly Basic Scientist Award from the International College of Neuropsychopharmacology, the Efron Award from the American College of Neuropsychopharmacology, as well as a NIMH MERIT award, a Distinguished Investigator award from the National Alliance for Research in Schizophrenia and Depression, the Judith Silver Memorial Investigator Award from the National Alliance for the Mentally Ill, and appointment as a Distinguished Professor of Neuroscience at the University of Pittsburgh. Dr. Grace was also recently elected as a Fellow in the American Association for the Advancement of Science. He is also a past member of the governing council of the American College of Neuropsychopharmacology and editor on numerous leading journals in the field.